دورية أكاديمية
أعرض في EDS

SARS-CoV-2 ORF8 Mediates Signals in Macrophages and Monocytes through MyD88 Independently of the IL-17 Receptor.

التفاصيل البيبلوغرافية
العنوان: SARS-CoV-2 ORF8 Mediates Signals in Macrophages and Monocytes through MyD88 Independently of the IL-17 Receptor.
المؤلفون: Ponde NO; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA., Shoger KE; Department of Immunology, University of Pittsburgh, Pittsburgh, PA., Khatun MS; Tulane University, New Orleans, LA., Sarkar MK; Department of Dermatology, University of Michigan, Ann Arbor, MI., Dey I; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA., Taylor TC; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA., Cisney RN; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA., Arunkumar SP; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA., Gudjonsson JE; Department of Dermatology, University of Michigan, Ann Arbor, MI., Kolls JK; Tulane University, New Orleans, LA., Gottschalk RA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA., Gaffen SL; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
المصدر: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2023 Jul 15; Vol. 211 (2), pp. 252-260.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Association of Immunologists Country of Publication: United States NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
أسماء مطبوعة: Publication: Bethesda, MD : American Association of Immunologists
Original Publication: Baltimore : Williams & Wilkins, c1950-
مواضيع طبية MeSH: COVID-19*/immunology , COVID-19*/virology , Open Reading Frames* , SARS-CoV-2*/metabolism, Animals ; Humans ; Mice ; Cytokines/metabolism ; Macrophages/metabolism ; Monocytes/metabolism ; Myeloid Differentiation Factor 88/genetics ; Myeloid Differentiation Factor 88/metabolism ; Receptors, Interleukin-17/genetics ; Receptors, Interleukin-17/metabolism
مستخلص: SARS-CoV-2 has caused an estimated 7 million deaths worldwide to date. A secreted SARS-CoV-2 accessory protein, known as open reading frame 8 (ORF8), elicits inflammatory pulmonary cytokine responses and is associated with disease severity in COVID-19 patients. Recent reports proposed that ORF8 mediates downstream signals in macrophages and monocytes through the IL-17 receptor complex (IL-17RA, IL-17RC). However, generally IL-17 signals are found to be restricted to the nonhematopoietic compartment, thought to be due to rate-limiting expression of IL-17RC. Accordingly, we revisited the capacity of IL-17 and ORF8 to induce cytokine gene expression in mouse and human macrophages and monocytes. In SARS-CoV-2-infected human and mouse lungs, IL17RC mRNA was undetectable in monocyte/macrophage populations. In cultured mouse and human monocytes and macrophages, ORF8 but not IL-17 led to elevated expression of target cytokines. ORF8-induced signaling was fully preserved in the presence of anti-IL-17RA/RC neutralizing Abs and in Il17ra-/- cells. ORF8 signaling was also operative in Il1r1-/- bone marrow-derived macrophages. However, the TLR/IL-1R family adaptor MyD88, which is dispensable for IL-17R signaling, was required for ORF8 activity yet MyD88 is not required for IL-17 signaling. Thus, we conclude that ORF8 transduces inflammatory signaling in monocytes and macrophages via MyD88 independently of the IL-17R.
(Copyright © 2023 by The American Association of Immunologists, Inc.)
References: Front Immunol. 2019 Sep 11;10:2107. (PMID: 31572359)
Immunity. 2022 Feb 8;55(2):237-253.e8. (PMID: 35081371)
Nat Rev Drug Discov. 2012 Oct;11(10):763-76. (PMID: 23023676)
J Immunol. 2008 Jan 1;180(1):655-63. (PMID: 18097068)
J Immunol. 2011 Nov 1;187(9):4389-91. (PMID: 22013204)
Nat Rev Rheumatol. 2020 Jun;16(6):335-345. (PMID: 32327746)
Nat Immunol. 2019 Dec;20(12):1594-1602. (PMID: 31745337)
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7506-11. (PMID: 17456598)
Sci Rep. 2017 Dec 22;7(1):18045. (PMID: 29273799)
Cell Host Microbe. 2016 Nov 9;20(5):596-605. (PMID: 27923703)
Nat Rev Immunol. 2020 Jun;20(6):345-346. (PMID: 32358580)
J Immunol. 2008 Aug 15;181(4):2799-805. (PMID: 18684971)
Front Genet. 2021 Sep 06;12:693227. (PMID: 34552615)
Mol Cell Biol. 2000 Feb;20(4):1436-47. (PMID: 10648628)
PLoS Pathog. 2023 Jan 23;19(1):e1011128. (PMID: 36689483)
Nat Immunol. 2007 Mar;8(3):247-56. (PMID: 17277779)
Cancer Res. 1999 Aug 1;59(15):3698-704. (PMID: 10446984)
Immunity. 2009 Jan 16;30(1):108-19. (PMID: 19144317)
Nat Med. 2020 Jun;26(6):842-844. (PMID: 32398875)
J Exp Med. 2019 Jan 7;216(1):195-214. (PMID: 30578323)
J Thorac Oncol. 2012 Jul;7(7):1091-100. (PMID: 22534817)
Viruses. 2023 Mar 29;15(4):. (PMID: 37112851)
J Am Soc Nephrol. 2021 Dec;32(12):3081-3098. (PMID: 35167487)
J Immunol. 2006 Jan 15;176(2):711-5. (PMID: 16393951)
J Immunol. 2010 Apr 15;184(8):4307-16. (PMID: 20231694)
mBio. 2022 Apr 26;13(2):e0040222. (PMID: 35343786)
Cell Host Microbe. 2016 Nov 9;20(5):606-617. (PMID: 27923704)
J Immunol. 1995 Dec 15;155(12):5483-6. (PMID: 7499828)
Science. 2020 May 1;368(6490):473-474. (PMID: 32303591)
J Immunol. 2007 Oct 15;179(8):5462-73. (PMID: 17911633)
Immunity. 1995 Dec;3(6):811-21. (PMID: 8777726)
Trends Immunol. 2017 May;38(5):310-322. (PMID: 28254169)
J Immunol. 2010 Jul 15;185(2):1063-70. (PMID: 20554964)
Immunity. 2020 Aug 18;53(2):384-397.e5. (PMID: 32673565)
Immunity. 2020 Mar 17;52(3):499-512.e5. (PMID: 32187518)
Int Immunol. 2023 Jan 21;35(1):43-52. (PMID: 36053553)
Elife. 2021 Mar 08;10:. (PMID: 33682678)
JCI Insight. 2018 May 3;3(9):. (PMID: 29720566)
Int Immunol. 2021 Nov 25;33(12):723-729. (PMID: 34611705)
Microb Cell Fact. 2007 Jan 03;6:1. (PMID: 17201926)
Curr Opin Immunol. 2020 Oct;66:50-56. (PMID: 32408109)
iScience. 2021 Apr 23;24(4):102293. (PMID: 33723527)
J Virol. 2007 Jan;81(2):813-21. (PMID: 17079315)
Sci Immunol. 2019 Jun 7;4(36):. (PMID: 31175175)
Immunity. 2011 Feb 25;34(2):149-62. (PMID: 21349428)
J Biol Chem. 2006 Aug 25;281(34):24138-48. (PMID: 16798734)
Science. 2022 Jul 8;377(6602):eabg9302. (PMID: 35709248)
Cell Host Microbe. 2023 Feb 8;31(2):243-259.e6. (PMID: 36563691)
Lancet. 2020 Aug 29;396(10251):603-611. (PMID: 32822564)
PLoS One. 2014 Dec 05;9(12):e113840. (PMID: 25478795)
Immunity. 2014 Jan 16;40(1):117-27. (PMID: 24412614)
J Immunol. 2006 Jul 1;177(1):36-9. (PMID: 16785495)
J Immunol. 2020 Aug 15;205(4):892-898. (PMID: 32651218)
J Transl Med. 2020 Apr 14;18(1):164. (PMID: 32290839)
Lancet Rheumatol. 2021 Oct;3(10):e690-e697. (PMID: 34396156)
J Immunol. 2005 Sep 1;175(5):3360-8. (PMID: 16116229)
Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859)
PLoS One. 2017 Oct 12;12(10):e0186281. (PMID: 29023500)
Cell Rep. 2022 Oct 18;41(3):111489. (PMID: 36260993)
Theranostics. 2021 Jul 6;11(16):8076-8091. (PMID: 34335981)
معلومات مُعتمدة: R35 HL139930 United States HL NHLBI NIH HHS; R01 AI162616 United States AI NIAID NIH HHS; P30 AR075043 United States AR NIAMS NIH HHS; R01 AI147383 United States AI NIAID NIH HHS; R35 GM146896 United States GM NIGMS NIH HHS; T32 AI089443 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Cytokines)
0 (Myeloid Differentiation Factor 88)
0 (Receptors, Interleukin-17)
0 (MYD88 protein, human)
تواريخ الأحداث: Date Created: 20230602 Date Completed: 20230718 Latest Revision: 20240716
رمز التحديث: 20240716
مُعرف محوري في PubMed: PMC10330444
DOI: 10.4049/jimmunol.2300110
PMID: 37265402
قاعدة البيانات: MEDLINE
الوصف
تدمد:1550-6606
DOI:10.4049/jimmunol.2300110